Insulet - PODD Stock Forecast, Price & News

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. It offers Omnipod System, a self-adhesive disposable tubeless Omnipod device that is worn on the body for up to three days at a time, as well as its wireless companion, the handheld personal diabetes manager. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, the Middle East, and Australia. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.

Analyst Ratings Changes

Several equities analysts recently weighed in on PODD shares. Morgan Stanley increased their price target on shares of Insulet from $244.00 to $273.00 and gave the stock an "equal weight" rating in a report on Monday, August 8th. Citigroup boosted their target price on shares of Insulet to $260.00 in a research report on Tuesday, August 9th. Raymond James increased their price target on Insulet from $262.00 to $280.00 in a research report on Friday, August 5th. Robert W. Baird lifted their price objective on Insulet from $245.00 to $300.00 and gave the company an "outperform" rating in a research note on Friday, August 5th. Finally, Wells Fargo & Company reduced their price target on Insulet from $357.00 to $345.00 in a research report on Friday, May 6th. Four equities research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company. According to MarketBeat.com, Insulet presently has a consensus rating of "Moderate Buy" and a consensus target price of $295.23.

Insulet Price Performance

NASDAQ:PODD traded up $4.72 on Thursday, hitting $271.32. The company had a trading volume of 311,368 shares, compared to its average volume of 560,281. The company has a debt-to-equity ratio of 3.28, a current ratio of 4.69 and a quick ratio of 3.54. The company has a market capitalization of $18.83 billion, a PE ratio of 542.20 and a beta of 0.73. Insulet has a 12-month low of $181.00 and a 12-month high of $324.81. The company's fifty day moving average price is $234.88 and its 200-day moving average price is $238.38.

Insulet (NASDAQ:PODD - Get Rating) last released its quarterly earnings results on Thursday, August 4th. The medical instruments supplier reported ($0.50) earnings per share for the quarter, missing the consensus estimate of $0.22 by ($0.72). Insulet had a return on equity of 13.83% and a net margin of 2.94%. The company had revenue of $299.40 million for the quarter, compared to analyst estimates of $290.87 million. During the same quarter last year, the company earned $0.10 EPS. The firm's revenue for the quarter was up 13.8% on a year-over-year basis. As a group, analysts predict that Insulet will post 0.87 earnings per share for the current year.

Insider Transactions at Insulet

In other news, COO Charles Alpuche sold 6,000 shares of the company's stock in a transaction on Monday, June 6th. The shares were sold at an average price of $215.32, for a total transaction of $1,291,920.00. Following the completion of the sale, the chief operating officer now owns 43,899 shares of the company's stock, valued at $9,452,332.68. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. In related news, COO Charles Alpuche sold 6,000 shares of the company's stock in a transaction dated Monday, June 6th. The shares were sold at an average price of $215.32, for a total value of $1,291,920.00. Following the completion of the sale, the chief operating officer now owns 43,899 shares of the company's stock, valued at $9,452,332.68. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Shacey Petrovic sold 15,000 shares of Insulet stock in a transaction dated Friday, July 1st. The stock was sold at an average price of $222.90, for a total transaction of $3,343,500.00. Following the transaction, the director now directly owns 13,695 shares in the company, valued at $3,052,615.50. The disclosure for this sale can be found here. Corporate insiders own 0.90% of the company's stock.